Randomized trial · people
VK2735: up to 14.7% weight loss at 13 weeks in VENTURE
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Every dose of VK2735 in this phase 2 trial led to weight loss over 13 weeks, and gut-related side effects were the main issue, reported less often as treatment went on.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2026
- Journal
- Obesity (Silver Spring)
What they tested
The team wanted to find which weekly doses of VK2735 lead to weight loss over 13 weeks.
How the study was done
A phase 2, randomized, double-blind, placebo-controlled trial that tested several doses of VK2735, given as a weekly shot under the skin, against placebo (a dummy shot) for 13 weeks. It enrolled adults with obesity, or overweight plus at least 1 weight-related health problem, and did not include people with diabetes.

Model. Individual results vary.
What they found
Average weight loss on VK2735 ranged from 9.2 kg (9.1%) in the 2.5 mg arm to 14.6 kg (14.7%) in the 15 mg arm, while the placebo group lost 1.8 kg (1.7%). Among people on VK2735, 93% (130/140) lost at least 5% of their starting weight, compared with 12% (4/34) on placebo. The most common side effects involved the stomach and gut, and people reported them less often once the dose had been stepped up and held steady.
What it doesn’t show
At 13 weeks, this trial is short and does not show what happens with longer use or after stopping. People with diabetes were not included, and the placebo group was small.
The paper
Bays et al. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026.
The compound
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.